SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,697.82 (-1.25%)
DOW   29,641.80 (-0.95%)
QQQ   275.20 (-1.63%)
MSFT   242.58 (-1.71%)
META   137.55 (-1.09%)
AMZN   118.45 (-1.54%)
TSLA   233.95 (-1.76%)
NVDA   125.89 (-4.12%)
NIO   14.43 (-2.30%)
AMD   64.50 (-4.94%)
T   15.26 (-0.39%)
MU   53.55 (-1.96%)
CGC   3.66 (-2.40%)
F   12.21 (-1.21%)
GE   66.01 (-0.32%)
DIS   98.75 (-1.29%)
AMC   7.08 (-0.56%)
PYPL   92.52 (-2.01%)
PFE   42.92 (-0.39%)
NFLX   236.00 (-1.67%)
S&P 500   3,697.82 (-1.25%)
DOW   29,641.80 (-0.95%)
QQQ   275.20 (-1.63%)
MSFT   242.58 (-1.71%)
META   137.55 (-1.09%)
AMZN   118.45 (-1.54%)
TSLA   233.95 (-1.76%)
NVDA   125.89 (-4.12%)
NIO   14.43 (-2.30%)
AMD   64.50 (-4.94%)
T   15.26 (-0.39%)
MU   53.55 (-1.96%)
CGC   3.66 (-2.40%)
F   12.21 (-1.21%)
GE   66.01 (-0.32%)
DIS   98.75 (-1.29%)
AMC   7.08 (-0.56%)
PYPL   92.52 (-2.01%)
PFE   42.92 (-0.39%)
NFLX   236.00 (-1.67%)
S&P 500   3,697.82 (-1.25%)
DOW   29,641.80 (-0.95%)
QQQ   275.20 (-1.63%)
MSFT   242.58 (-1.71%)
META   137.55 (-1.09%)
AMZN   118.45 (-1.54%)
TSLA   233.95 (-1.76%)
NVDA   125.89 (-4.12%)
NIO   14.43 (-2.30%)
AMD   64.50 (-4.94%)
T   15.26 (-0.39%)
MU   53.55 (-1.96%)
CGC   3.66 (-2.40%)
F   12.21 (-1.21%)
GE   66.01 (-0.32%)
DIS   98.75 (-1.29%)
AMC   7.08 (-0.56%)
PYPL   92.52 (-2.01%)
PFE   42.92 (-0.39%)
NFLX   236.00 (-1.67%)
S&P 500   3,697.82 (-1.25%)
DOW   29,641.80 (-0.95%)
QQQ   275.20 (-1.63%)
MSFT   242.58 (-1.71%)
META   137.55 (-1.09%)
AMZN   118.45 (-1.54%)
TSLA   233.95 (-1.76%)
NVDA   125.89 (-4.12%)
NIO   14.43 (-2.30%)
AMD   64.50 (-4.94%)
T   15.26 (-0.39%)
MU   53.55 (-1.96%)
CGC   3.66 (-2.40%)
F   12.21 (-1.21%)
GE   66.01 (-0.32%)
DIS   98.75 (-1.29%)
AMC   7.08 (-0.56%)
PYPL   92.52 (-2.01%)
PFE   42.92 (-0.39%)
NFLX   236.00 (-1.67%)
NYSE:NUVB

Nuvation Bio - NUVB Price Target & Analyst Ratings

$2.50
0.00 (0.00%)
(As of 10/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.40
$2.52
50-Day Range
$1.99
$3.08
52-Week Range
$1.92
$10.45
Volume
536,676 shs
Average Volume
629,123 shs
Market Capitalization
$545.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Nuvation Bio Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$4.00
60.00% Upside
High Prediction$5.00
Average Prediction$4.00
Low Prediction$2.50
TypeCurrent
10/7/21 to 10/7/22
1 Month Ago
9/7/21 to 9/7/22
3 Months Ago
7/9/21 to 7/9/22
1 Year Ago
10/7/20 to 10/7/21
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.00$4.00$14.33$17.40
Predicted Upside60.00% Upside53.65% Upside196.76% Upside52.07% Upside
Get Nuvation Bio Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.


NUVB Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NUVB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nuvation Bio Stock vs. The Competition

TypeNuvation BioMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.68
2.49
Consensus RatingModerate BuyBuyHold
Predicted Upside60.00% Upside1,082.54% Upside29.01% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
18
62.07%
Underperform Votes
11
37.93%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
853
68.40%
Avg. Underperform Votes
394
31.60%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/22/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Burns
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$14.00 ➝ $4.50+59.01%
8/2/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$8.00 ➝ $2.50+0.40%
8/2/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
8/1/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$17.00 ➝ $5.00+100.80%
4/6/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$15.00+38.25%
3/8/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$20.00+84.16%
3/8/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
(Data available from 10/7/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NUVB Price Target - Frequently Asked Questions

What is Nuvation Bio's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Nuvation Bio stock is Moderate Buy based on the current 2 hold ratings and 2 buy ratings for NUVB. The average twelve-month price prediction for Nuvation Bio is $4.00 with a high price target of $5.00 and a low price target of $2.50. Learn more on NUVB's analyst rating history.

Do Wall Street analysts like Nuvation Bio more than its competitors?

Analysts like Nuvation Bio less than other Medical companies. The consensus rating for Nuvation Bio is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how NUVB compares to other companies.

Do MarketBeat users like Nuvation Bio more than its competitors?

MarketBeat users like Nuvation Bio less than other Medical companies. 62.07% of MarketBeat users gave Nuvation Bio an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Is Nuvation Bio being downgraded by Wall Street analysts?

Over the previous 90 days, Nuvation Bio's stock had 2 downgrades by analysts.

Does Nuvation Bio's stock price have much upside?

According to analysts, Nuvation Bio's stock has a predicted upside of 53.65% based on their 12-month price targets.

What analysts cover Nuvation Bio?

Nuvation Bio has been rated by BMO Capital Markets, BTIG Research, HC Wainwright, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:NUVB) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.